pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › RHHBY

RHHBY PDUFA Date: Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy

FDA decision (PDUFA) target 2026-10-09 · Roche Holding AG ADR · Stage III colon cancer

RHHBY run-up into the PDUFA (last ~120 days)

$60.58$47.39
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-10-09
Drug / candidateTecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy
IndicationStage III colon cancer
CompanyRoche Holding AG ADR
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.gov—

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the RHHBY PDUFA date?
The FDA PDUFA target date for RHHBY (Roche Holding AG ADR) is 2026-10-09 for Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy. Dates are company/FDA-sourced and can slip — verify against primary filings.
What is RHHBY's drug Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy?
Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy is Roche Holding AG ADR's candidate under FDA review for Stage III colon cancer.
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.